tirzepatide surpass 4 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial AstraZeneca's Bydureon gets a Reagents Buy More Save More:Triple Pack

tirzepatide surpass 4 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial AstraZeneca's Bydureon gets a Reagents Buy More Save More:Triple Pack

AstraZeneca's Bydureon gets a facelift, but can it stand out in a GLP-1 market that's only getting tougher? | Fierce Pharma

Individual experiences vary, and side effects often improve with proper titration

Reagents

Buy More Save More:Triple Pack

A post-meeting report recorded seven favorable votes, five opposing votes, and one abstention